You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Merck
Medtronic
Express Scripts
Boehringer Ingelheim

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021476


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 021476 describes LUNESTA, which is a drug marketed by Sunovion Pharms Inc and is included in one NDA. It is available from two suppliers. Additional details are available on the LUNESTA profile page.

The generic ingredient in LUNESTA is eszopiclone. There are twenty drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the eszopiclone profile page.
Summary for 021476
Tradename:LUNESTA
Applicant:Sunovion Pharms Inc
Ingredient:eszopiclone
Patents:0
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 021476
Suppliers and Packaging for NDA: 021476
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LUNESTA eszopiclone TABLET;ORAL 021476 NDA PD-Rx Pharmaceuticals, Inc. 55289-014 55289-014-30 30 TABLET, COATED in 1 BOTTLE, PLASTIC (55289-014-30)
LUNESTA eszopiclone TABLET;ORAL 021476 NDA Sunovion Pharmaceuticals Inc. 63402-190 63402-190-30 30 TABLET, COATED in 1 BOTTLE (63402-190-30)
Paragraph IV (Patent) Challenges for 021476
Tradename Dosage Ingredient NDA Submissiondate
LUNESTA TABLET;ORAL eszopiclone 021476 2008-12-15

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength1MG
Approval Date:Dec 15, 2004TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Dec 15, 2004TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength3MG
Approval Date:Dec 15, 2004TE:ABRLD:Yes

Expired US Patents for NDA 021476

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004   Start Trial   Start Trial
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004   Start Trial   Start Trial
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-003 Dec 15, 2004   Start Trial   Start Trial
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-003 Dec 15, 2004   Start Trial   Start Trial
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
McKinsey
Baxter
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.